Theranos presented to investors with the goal of becoming the standard for improving drug therapies. Its initial market is phase IV clinical trials, using a product platform of cartridges, readers, and informatics services. Founded in 2003 with 50 employees, Theranos aims to generate $120-300M in revenue over 1.5 years through deals with pharmaceutical companies. The company's system allows for simultaneous quantitative measurement of drugs and biomarkers from small blood samples, returning results comparable to gold standards within 30 minutes. Theranos' value proposition is improving drug labels and safety by enabling real-time pharmacokinetic and pharmacodynamic monitoring during trials and treatment.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Pitch Deck for Medella, an open digital medical platform for patients, hospitals, independent doctors and care teams. Purpose of the presentation - to help raise money. Build on BaseTemplates Pitch Deck Template
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Pitch Deck for Medella, an open digital medical platform for patients, hospitals, independent doctors and care teams. Purpose of the presentation - to help raise money. Build on BaseTemplates Pitch Deck Template
AppVirality - Plug & Play growth hacking toolkit for Mobile apps.
We help app developers implement Uber/Lyft like in-app referrals under 30 minutes. No coding required.
Checkout - http://appvirality.com
🔮 Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
🔮 The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
🔮 Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
The Pitch Deck We Used To Raise Over $1 MillionStuart Logan
Twine has raised over $1 million. This is one of the pitchdecks we used. Here is the story:
https://www.twine.fm/blog/pitch-deck-used-to-raise-a-million/
Note, I removed 5 sensitive slides in the Appendix: Financials, Projections, Competition, and Marketing Strategy.
Bad Blood Summary- Theranos- Elizabeth Holmes Sunita Sharma
Bad Blood: Secrets and Lies in a Silicon Valley Startup is a nonfiction book by journalist John Carreyrou, covers the rise and fall of Theranos, the multibillion-dollar biotech startup headed by Elizabeth Holmes. I have made this presentation as part of my business ethics major.
Peter Thiel's Venture Capital Pitch Deck TemplateAA BB
Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
Fintech, Online Brokerage & Online Betting - Presentation by Valentin Stalf, Co-Founder & CEO of N26 at the NOAH Conference London 2016, Old Billingsgate on the 11th of November 2016.
After studying over 100 venture-backed healthcare companies, we present the definitive benchmarks for what growing a health tech business should look like at every stage.
Read the full article here: https://www.bvp.com/atlas/how-to-scale-a-health-tech-business-to-100-million-arr-and-beyond
If you’re an investor who’d like to find out more about Hive, get in touch with the founder directly via john.ryder@hive.hr, or alternatively drop me an email at alex@mountsideventures.com
(Pitch Deck): How FTX raised over $1 billionPitch Decks
FTX was arguably the market-leading cryptocurrency exchange before it's highly-publicized liquidity crisis and ensuing bankruptcy filing in late 2022.
FTX (once valued over $32 billion) collapsed in a matter of days in November 2022 after it was revelaed that founder Bankman-Fried had secretly shifted $10 billion of FTX customer deposits to Alameda.
Despite their recent failures, one cannot overlook that FTX was incredibly successful in fundraising in a challenging environment:
They raised their first seed round in 2018 in the midst of the crypto-winter, and raised over $1.8 billion since.
FTX raised multiple rounds led by Sequoia, with participation from notable VC funds like Tiger Global, Softbank, Lightspeed Venture Partners, ICONIQ Growth, and more.
Here's an inside look at an FTX pitch deck from May 2021, presumably used to raise their $1B Series B round announced in June of the same year:
🔮 Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
🔮 The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
🔮 Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
Mapme Investor Deck.
The deck we originally used to raise our seed round of $1M. See the progress we've made at www.mapme.com. Welcome to try it out and create a map.
Any questions? I'm at ben@mapme.com
AppVirality - Plug & Play growth hacking toolkit for Mobile apps.
We help app developers implement Uber/Lyft like in-app referrals under 30 minutes. No coding required.
Checkout - http://appvirality.com
🔮 Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
🔮 The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
🔮 Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
The Pitch Deck We Used To Raise Over $1 MillionStuart Logan
Twine has raised over $1 million. This is one of the pitchdecks we used. Here is the story:
https://www.twine.fm/blog/pitch-deck-used-to-raise-a-million/
Note, I removed 5 sensitive slides in the Appendix: Financials, Projections, Competition, and Marketing Strategy.
Bad Blood Summary- Theranos- Elizabeth Holmes Sunita Sharma
Bad Blood: Secrets and Lies in a Silicon Valley Startup is a nonfiction book by journalist John Carreyrou, covers the rise and fall of Theranos, the multibillion-dollar biotech startup headed by Elizabeth Holmes. I have made this presentation as part of my business ethics major.
Peter Thiel's Venture Capital Pitch Deck TemplateAA BB
Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
Fintech, Online Brokerage & Online Betting - Presentation by Valentin Stalf, Co-Founder & CEO of N26 at the NOAH Conference London 2016, Old Billingsgate on the 11th of November 2016.
After studying over 100 venture-backed healthcare companies, we present the definitive benchmarks for what growing a health tech business should look like at every stage.
Read the full article here: https://www.bvp.com/atlas/how-to-scale-a-health-tech-business-to-100-million-arr-and-beyond
If you’re an investor who’d like to find out more about Hive, get in touch with the founder directly via john.ryder@hive.hr, or alternatively drop me an email at alex@mountsideventures.com
(Pitch Deck): How FTX raised over $1 billionPitch Decks
FTX was arguably the market-leading cryptocurrency exchange before it's highly-publicized liquidity crisis and ensuing bankruptcy filing in late 2022.
FTX (once valued over $32 billion) collapsed in a matter of days in November 2022 after it was revelaed that founder Bankman-Fried had secretly shifted $10 billion of FTX customer deposits to Alameda.
Despite their recent failures, one cannot overlook that FTX was incredibly successful in fundraising in a challenging environment:
They raised their first seed round in 2018 in the midst of the crypto-winter, and raised over $1.8 billion since.
FTX raised multiple rounds led by Sequoia, with participation from notable VC funds like Tiger Global, Softbank, Lightspeed Venture Partners, ICONIQ Growth, and more.
Here's an inside look at an FTX pitch deck from May 2021, presumably used to raise their $1B Series B round announced in June of the same year:
🔮 Want more VC/investment startup pitch decks? We’ve centralised ALL succesful investor pitch decks at: https://chagency.co.uk/getstartupfunding — check all of them out
🔮 The effort is adhering to the ideology of “The Future Of Freemium” — read more here: https://chagency.co.uk/blog/ceo/the-future-of-freemium-how-to-get-peoples-attention/
🔮 Our library of pitch decks will not have any advertisement, only a signature. We are a design agency that helps SaaS CEOs reduce user churn.
Mapme Investor Deck.
The deck we originally used to raise our seed round of $1M. See the progress we've made at www.mapme.com. Welcome to try it out and create a map.
Any questions? I'm at ben@mapme.com
The 2014 Global Traveler Study offers hotel and restaurant executives detailed insight into the mind of the modern traveler. Global consumer surveys across a wide range of demographics has uncovered traveler preferences for the use of mobile devices, social media, and loyalty programs in their interactions with hotels and restaurants. Findings reveal that consumer purchasing patterns are shifting towards increasingly mobile transactions. Meanwhile, loyalty is evolving to value personalized offers and rewards, and social media has potential to become a valuable channel for ecommerce. The valuable insight contained in this 2014 Global Traveler Study can help operators shape their digital engagement strategies on an ongoing basis.
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for ETS’s testing and simulation services for carbon nanotubes (CNTs). CNTs have unique characteristics that make them useful for many hi-tech systems for the military and consumer electronics. However, life cycle testing and simulation are needed for CNTs to be effectively used in these applications. ETS provides these kinds of services for military and consumer electronics firms and would like to add CNTs to its expertise. These slides describe the specific value proposition for military and consumer electronic firms and other aspects of the business model such as the method of value capture, scope of activities, and method of strategic control.
Levende selvledelse - Sundt engagement der skaber værdi | Tommy Kjaer Lassen ...Tommy Kjær Lassen
Inspiration til levende selvledelse, det sunde og værdiskabende engagement. Materialet er udviklet i forbindelse med en phd-afhandling om eksistentiel selvledelse.
Somos una consultora especializada en la Gestión de Proyectos, proveemos los conceptos,métodos,técnicas y herramientas precisas y concretas para asegurar una correcta planificación, seguimiento y control de las actividades.
What's New in SharePoint 2016 for End Users Webinar with IntlockVlad Catrinescu
SharePoint 2016 RTM is almost out, and with the Beta 2 being 99% feature complete, we already have a good idea of what will be in the final product. In this short webinar, we will look at all the new cool stuff in SharePoint Server 2016 from and End User point of view! SharePoint 2016 includes some awesome features such as DLP, Durable Links as well as Microsoft’s investments in Hybrid!
SDTM Training for personnel with Junior and Intermediate level Clinical Trial Experience. Covers summary of most domains. Salient features include order of domain creation, importance of making programming Data/Metadata Driven, Nature of Clinical Raw Data, Summary of the Clinical Trial process with regards to the data flow to arrive at the Study data to be submitted to regulatory authorities like FDA, Importance of deriving ADAM from SDTM and not directly from raw data, Information has been put together from variety of sources including my own programming work.
Introduction to Regulatory Affairs - Pauwels Consulting AcademyPauwels Consulting
On Tuesday, June 14, our colleagues Fiorenzo Savoretti, Senior Regulatory and Quality Consultant at Pfizer and Nick Deschacht, Senior RA Consultant at GSK, gave an interesting “Introduction to Regulatory Affairs”.
Fiorenzo and Nick talked about RA and their projects, each from their unique angle. They delivered their presentations for ## attendees at our Brussels office at the Lambroekstraat 5a in Diegem.
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
The stages of Drug Discovery and Development processA M O L D E O R E
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug
Cell & Gene Therapy post-approval solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
This SlideShare gives an overview on how a drug is discovered, researched, developed, tested and reviewed for approval. It follows the current standard of approval set by the Food and Drug Administration (FDA), a federal agency of the United States Department of Health and Human Services. The process is generally divided into 4 Stages: Pre-Clinical, Clinical, New Drug Application (NDA) Review & Post-Marketing.
Arizona Center for Innovation (AzCI) presents: FDA Drug Development 101 - I discovered a drug which will cure the world disease - now what!
This presentation is part of a series developed for a workshop on "How to Navigate the Biotech Regulatory Process"
The Arizona Center for Innovation is an incubator and innovation center and provides resources in support of startups getting to the next level and become successful enterprises.
An introduction for those who may be interested in a career in clinical research, but need to understand the industry and their potential for a role in it.
Provides an overview of the later stages of drug development, explaining the phases of drug studies and explores in brief the key roles for those participating.
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
Real-Time Data. Real-World Impact. Info sheet Covance
Data can help, but simply accessing more data only muddies your decision making. With Covance, you get the right analysis on the right data to empower your studies.
Cento Ventures Southeast Asia Tech Investments 2018Renata George
Top three things to know about Southeast Asia Tech Investment Activity in 2018 and the full report by Cento Ventures:
- Exits in the range of USD50M - USD100M are happening more often
- VCs actively invest in fintech, real estate, logistics, and business automation startups
- Lack of seed capital - Deals smaller than USD0.5M continue to decline
Reading this presentation will let you know everything about the boiling digital market in Russia, from its roots in Russian culture, to the innovative startups of nowadays.
Mei Meng — Инновационная модель Китая на примере Научного парка при Университ...Renata George
Summit of Innovation Economy Creators.
Mei Meng.
Основатель Технопарка университета Цинхуа TusPark, председатель управляющей компании Технопарка TusPark Co. Ltd., глава Центра развития Технопарка. Постоянный член правления Китайской Ассоциации технопарков при университетах. Заместитель генерального секретаря Фонда по образованию университета Цинхуа.
Herbert Chen — How to Make the Dream Become True? Summit of Innovation Econom...Renata George
Summit of Innovation Economy Creators.
Herbert Chen.
Вице-президент Научного парка при Университете Цинхуа. Заместитель директора Центра развития Научного парка при Университете Цинхуа в Пекине. Директор Пекинского подразделения Международной ассоциации научных парков, IASP. Постоянный участник и спикер международных конференций по инновационному развитию.
E. Anthony Tan — Fostering Innovation Development - Hong Kong ExperienceRenata George
Summit of Innovation Economy Creators.
Anthony E. Tan.
Исполнительный директор Корпорации Научных и технологических парков Гонконга, ранее консультант для DuPont по инвестициям в сфере создания новых материалов, биомедицине, химических и агрохимических препаратов. Более 30 лет создавал хай-тек инфраструктуры в АТР для DuPont (в Шанхае, Пекине и дельте реки Жемчужная). Постоянный участник международных конференций по инновациям. Прекрасно известен во всём мире.
John Kao — Skolkovo Summit of Innovation Economy CreatorsRenata George
Summit of Innovation Economy Creators.
John Kao.
Mr. Creativity - The Economist. Международный консультант BASF, American Express, Nike, Intel, Nissan, PricewaterhouseCoopers и др. Советник Х.Клинтон по вопросам инноваций и конкурентоспособности США. Успешный предприниматель, на его счету несколько стартапов - BioSurface Technology, Phylotech и др. Основатель - НКО The Institute for Large Scale Innovation. Основал компанию Idea Factory, «чтобы помогать крупным фирмам в создании революционных новаторских замыслов».
Chintay Shih — Role of Public Research InstitutesRenata George
Summit of Innovation Economy Creators.
Chintay Shih.
Стоял у истоков технологического развития Тайваня. Советник по науке и технологиям правительства Тайваня. Специальный советник Азиатско-Тихоокеанского совета лидерства (союз промышленников АТР). 9 лет возглавлял Институт исследований промышленных технологий Тайваня. Профессор и декан факультета управления технологиями Цинхуа. В совете директоров ряда венчурных компаний. Руководил Китайским институтом инженеров, Азиатско-тихоокеанской ассоциацией по защите интеллектуальной собственности, Ассоциацией полупроводниковой промышленностиТайваня, Китайским обществом управления технологиями.
Mervi Käki — Creating world innovation centres. Skolkovo Summit of Innovation...Renata George
Summit of Innovation Economy Creators.
Mervi Käki.
2001-2008 - различные управляющие должности в компании Technopolis PLC. Создатель технопарка Отаниеми, Хельсинки. Запустила и координировала программы по развитию инноваций в регионе Вантаа. Координировала и реорганизовала технопарк Иннополи. Партнёр, управляющий директор и главный консультант в компании InnoPraxis International Ltd. Известный специалист по инновациям и участник международных конференций.
Prof. Se-Jung Oh — Networking between Academia, Public Research Institutes an...Renata George
Global Summit of Innovation Economy Creators.
Se Jung Oh.
Председатель Национального исследовательского фонда Кореи. Председатель Корейско-американского центра по научному сотрудничеству. Советник правительства Кореи по научно-технологической политике с 1989 г. 2007-2008 - член правительственного комитета по стимулированию фундаментальных исследований. Глава Комитета по разработке специальной инициативы по повышению привлекательности ВУЗов и исследовательских центров Кореи (World Class Universities). Профессор Государственного университета Сеула (ГУС). Известный исследователь (физика и электроника).
Sven-Thore Holm — Global Summit of Innovation Economy CreatorsRenata George
Global Summit of Innovation Economy Creators.
Sven-Thore Holm.
Гендиректор Lundavision AB, основатель шведского Ideon Science Park. Исполнительный директор Фонда по передаче технологий, Лунд, Швеция (обучение предпринимательству, помощь в создании стартапов, получении патентов на разработки, начальное финансирование). Состоит в рабочей группе «Сколково». В совете директоров ряда инновационных институтов и компаний в Швеции и Дании. Консультировал правительство и компании Австралии и Китая по вопросам инноваций.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Key Trends Shaping the Future of Infrastructure.pdfCheryl Hung
Keynote at DIGIT West Expo, Glasgow on 29 May 2024.
Cheryl Hung, ochery.com
Sr Director, Infrastructure Ecosystem, Arm.
The key trends across hardware, cloud and open-source; exploring how these areas are likely to mature and develop over the short and long-term, and then considering how organisations can position themselves to adapt and thrive.
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
2. 2Confidential & Proprietary
Theranos, Inc.
Our immediate goal is to become the standard for improving
the efficacy and risk/benefit and safety profile of every
therapy.
Initial Market: Phase IV Clinical trials
Product Platform:
System: Cartridges, Readers, Informatics Service
Founded 2003
Menlo Park, CA
50 Employees
3. 3Confidential & Proprietary
Theranos Today
6 Deals, 5 companies: $6-12M for validation phase
6 Phase IVs: $20-$50M each
$120 - $300M revenue in next 1.5 years
10 companies and 1 government agency: 15 additional deals
$21-52M for validation
$300-$750M for phase IVs
Existing deals: $120M - $1.5Bn in revenue
Improve label, validate efficacy and preempt liabilities
4. 4Confidential & Proprietary
Management
Elizabeth Holmes, President and CEO
Left Stanford Chemical and Electrical Engineering to found Theranos, also Genencor,
Genome Institute Singapore
Howard Bailey, CFO
Former CFO who took QED and Photon Dynamics public, also CFO Occam, C-Cube, and
Controller, Intel
Diane Parks, CCO
Former Senior Vice President, Biotherapeutics and Managed Care, Genentech, also Vice
President, Marketing, Aventis
John Howard, Senior VP, Products
Former President, Panasonic Semiconductor, also President, IBM Microelectronics Division
Dr. Ian Gibbons, Senior Director Assay Development
Former Senior Director, Syva, ACLARA, Biotrack, AmCell, First Medical
Tim Kemp, Senior Director Informatics Systems
Former lead systems engineer, IBM, Embedded Systems
Board of Directors:
Donald L. Lucas, Chairman of the Board
46-year veteran of the venture capital business
Elizabeth Holmes
CEO, Theranos
Peter Thomas
Founder and Managing Director, ATA Ventures; General Partner, Institutional Venture Partners
Channing Robertson
Stanford Senior Associate Dean of Engineering
5. 5Confidential & Proprietary
What is our system?
0
2E-11
4E-11
6E-11
8E-11
1E-10
1.2E-10
1.00E-12 1.00E-11 1.00E-10 1.00E-09 1.00E-08
Concentration (M)
BoundLabel(M)
Competitive
Two Step
www.theranos.com
7. 7Confidential & Proprietary
Theranos ABCS™: Ambulatory BioInformatics
Communications System
Effective narrow range therapy through post-prescription
monitoring of the total available patient base.
Telecommunications
Videoconferencing
8. 8Confidential & Proprietary
Product Features
Use: Simultaneous quantitative measurement of drugs and
treatment-related biomarkers
Sample Size: 5-10µL of blood
Time: Multiplex assays complete in < 30 minutes
Calibration/Control: On board with each measurement
Operating Principle: Chemiluminescent/Immunoassay
Dynamic Range: Low picogram/mL – high microgram/mL
Accuracy: Results comparable to “gold standards”
Precision: Average total 5-7% Coefficient of Variation or better
Data Reporting: Immediate upload from secured server
Attractiveness: New assays can be developed and implemented
within about three months and can be fully developed at ISO 9000
standards within about six months.
9. 9Confidential & Proprietary
Value Proposition
Increase pharmaceutical sales by improving the label of a
compound
Remove black boxes
Safely sell to total available patient base
Introduce existing compounds to market (rather than relying heavily
on gene sequencing and new discoveries)
Increase the number of patients enrolling in trials and reduce drop-
outs
Increase compliance
10. 10Confidential & Proprietary
First course of infusion chemotherapy with
Theranos monitoring
First course of treatment
(Drug level too high)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
-2.0 -1.0 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Time, hours
Parameter
First course dose
First course drug level
Drug level target
Standard dose rate; patient is not eliminating drug rapidly and drug
concentration increases over the target level to a toxic level.
11. 11Confidential & Proprietary
Second course of infusion chemotherapy with
Theranos monitoring
Second course (Drug dose reduced)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
-2.0 -1.0 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Time, hours
Parameter
Second course dose
Second course drug level
Drug level target
Same patient, second course of therapy; dose is lowered based
on Theranos results >> drug level is at target.
12. 12Confidential & Proprietary
Dose Customization
Drug dose adjusted in course
0.0
0.5
1.0
1.5
2.0
2.5
3.0
-2.0 -1.0 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Time, hours
Parameter
First course, drug dose
corrected in course
Drug level
Drug level target
Same patient but in the first course rapid (within one hour)
feedback from Theranos monitor leads to a decision to stop the
infusion. Drug level drops from toxic to target.
13. 13Confidential & Proprietary
Real-time PK/PD Monitoring
Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity
resuced to accepatable level
0
0.2
0.4
0.6
0.8
1
1.2
1.4
-10.0 0.0 10.0 20.0 30.0 40.0 50.0
Time, days
ParameterValue
Drug Dose
Drug Level
Effect marker
Toxicity marker
Tox. Alert Level
reduced to acceptable level
14. 14Confidential & Proprietary
Total Available Market:
Phase IV Clinical Trials
Phase IV Clinical Market = $39 Billion per year
Number of ongoing trials per year = 600 to 800
Average Theranos Revenue per trial = $50M
$7,500 “Information Fee” per patient for every four months
Average: 2,000 to 10,000 patients per trial
15. 15Confidential & Proprietary
Total Available Market:
Pharmaceutical preclinical market
Pre-clinical Market = $10 billion per year
$5M annual revenue per research group
133 groups per pharmaceutical company
15 companies of this size
Note: These numbers exclude sales to one of the
largest preclinical market segments: academic
institutions.
16. 16Confidential & Proprietary
Theranos Value Proposition
Revenue:
Information fee includes use of
Readers
Cartridges
ABCS informatics, patient diary and data integration service
70% margins
Requisite solution for improving labels or preempting liabilities
Cost to pharmaceutical companies is 20-30% less than
current costs of equivalent testing through clinicians office
17. 17Confidential & Proprietary
Pains In The Existing Marketplace
Adverse Drug Reactions reduce sales and keep some drugs off
the market
Pharmacogenomic tests (diagnostics) do not eliminate adverse
drug reactions
And screen some patients who could safely benefit from a drug
No mechanism to measure the effect of environmental factors on
drug efficacy
No continuous monitoring to determine the correct dosage
Current testing procedures too expensive or impossible for some
drugs
18. 18Confidential & Proprietary
Theranos Solution
Monitoring can take place anywhere and can be done by anyone
Monitoring can be as frequent as needed with little increase in cost
Results compare to / beat those obtained by a blood lab
Results are available in minutes
Warning to doctor can be sent within minutes of a test
Effectiveness of dose can be monitored in real time
Drug-drug combinations can be monitored to improve the label
Drugs can be prescribed with monitoring devices to prevent ADRs
Instant analysis and availability of related data improve speed and
effectiveness of trials
Consumer WWW increases value of therapy: Informs patients, drives
compliance and increases patient adherence to given drug
19. 19Confidential & Proprietary
Drivers for Success
First mover advantage
Combination of several different technologies makes
reproducing the solution difficult
Innovation Pipeline: Next generation systems
Strong Customer Base
Speed to Market and Focus on Quality
Patents
Management and Culture
20. 20Confidential & Proprietary
Offering
Objective: Pre-IPO transaction to facilitate rapid scaling of
Theranos production and manufacturing infrastructure and
add to Theranos business development and sales force.
CFP
Offering: $30M
Existing Investors: $15-20M
New Investors: $10-15M
21. 21Confidential & Proprietary
Existing Investors
Lead investor profiles:
Series A
Chang,Chang, EsoomEsoom TaipeiTaipei: Multi-billion dollar distribution group; leading distributors of high
technology devices in Asia with headquarters in China and in Taiwan.
Continental Properties CompanyContinental Properties Company: Fund lead by John Schweitizer and Stephen Feinberg,
director of MD Anderson, leading center in innovative cancer treatment, cutting-edge
research and clinical trials.
Draper FisherDraper Fisher JurvetsonJurvetson: Draper Fisher Jurvetson is a global network of affiliated venture
funds with over $3 billion in capital commitments and offices in the major technology centers
around the world.
Jupiter PartnersJupiter Partners: Fund lead by John Bryan, limited partner in numerous venture capital and
private equity funds and leading investor in companies ranging from Amgen to Hewlett
Packard.
PalmieriPalmieri TrustTrust: Fund lead by Victor Palmieri, business takeover financier; director of
numerous high growth companies including Phillips Petroleum, the Pennsylvania Company,
Arvida Corporation, Outlet Communications, the William Carter Company, Broadcasting
Partners, and Mullin Consulting and a Trustee of The Rockefeller Foundation.
Series B
Donald L Lucas fund: Premier Silicon Valley venture capital veteran (note biography in board
profile document)
ATA Ventures (Early Stage Venture Capital)
Larry Ellison, Tako Ventures
Dixson Doll (Doll Capital Management)
Ray Bingham, BJ Cassin, other private equity investors
22. 22Confidential & Proprietary
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1 10 100 1000 10000 100000
Concentration of TxB2 (pg/mL)
Normalizedresponse
Theranos Assay
Conventional Assay
0
10000
20000
30000
40000
50000
10 100 1000 10000 100000
Concentrationof TxB2 (pg/mL)
Signal(RLU)
Sample 4
Sample 5
Calibration
1.0
2.0
3.0
4.0
5.0
1.0 2.0 3.0 4.0 5.0
Spiked Concentration pg/mL (log scale)
CalculatedConcentrationpg/mL(logscale)
All data
Subject 4
Subject 5
Linear (All data)
Technology: Theranos System versus Today’s Lab
0.1
1
10
100
1000
10000
100000
0.1 1 10 100 1000 10000 100000
Actual (pg/mL, 4x)
Measured(pg/mL,4x)
5N+1
5N-1
5A-1
5F-2
4N+2
4A-2
4N-3
4F-3
Luminometer correlation
y = 0.9334x + 0.3992
R2 = 0.9915
R = 0.995
2.0E+00
2.5E+00
3.0E+00
3.5E+00
4.0E+00
4.5E+00
5.0E+00
5.5E+00
6.0E+00
6.5E+00
7.0E+00
2.0E+00 3.0E+00 4.0E+00 5.0E+00 6.0E+00 7.0E+00
Log MD response (counts/sec)
LogTheranosResponse(Counts/sec)
Luminometer correlation
Linear (Luminometer correlation)
Upper end of linear range
Projected signal
modulation of
Theranos Chip-
based assay in
5 uL volume
On chip Chemiluminescence enables greater sensitivity than the clinical
lab
23. 23Confidential & Proprietary
0
2000
4000
6000
8000
10000
12000
1 10 100 1000 10000 100000
Progesterone concentration in diluted sample (pg/ml)
Signal
Computation of results
Measured signal
(sent to Theranos
server)
Dose-
response
relationship
(Factory
calibration)
Derived
concentration
Concentration in sample = Signal >> Derived conc. * Dilution factor (fixed)
Computation performed at Theranos server
Chemistry is calibrated through Theranos server by comparing results
on cartridge to known results for calibration wells in database so as to
preempt use of environmentally deteriorated cartridges